InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.06), MarketWatch Earnings reports.
Shares of InflaRx traded up $0.61, hitting $35.00, during trading hours on Friday, MarketBeat Ratings reports. 53,497 shares of the company’s stock were exchanged, compared to its average volume of 65,525. InflaRx has a fifty-two week low of $34.10 and a fifty-two week high of $34.79.
IFRX has been the subject of several research analyst reports. Leerink Swann upped their target price on InflaRx from $31.00 to $36.00 and gave the stock an “outperform” rating in a research note on Monday, April 2nd. B. Riley initiated coverage on InflaRx in a research note on Thursday, February 8th. They set a “buy” rating and a $40.00 target price for the company. Zacks Investment Research downgraded InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, April 7th. Finally, ValuEngine raised InflaRx from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. InflaRx has a consensus rating of “Buy” and a consensus target price of $35.75.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.